Sarasota, FL, March 29, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Leukemia Therapeutics Market by Type (Acute, Chronic and other), Therapy (Chemotherapy, Biological Therapy, Radiation Therapy, Targeted Therapy and Others) and Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022”. According to the report, global leukemia therapeutics market was valued at approximately USD 9.44 billion in 2016 and is expected to generate revenue of around USD 11.97 billion by end of 2022, growing at a CAGR of around 4.1% between 2017 and 2022. 

Leukemia is cancer of blood cells. Blood cells are originated from hematopoietic stem cells (HSCs) in the bone marrow and undergo maturation process called hematopoiesis. Multipotent hematopoietic stem cells undergo differentiation in the process of maturation to give rise progenitor cells of myeloid and lymphoid origin. Myeloid cells include monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, dendritic cells and megakaryocytes or platelets. Lymphoid cells include T cells, B cells, and natural killer cells. Acute leukemia is fast growing and worsens quickly, wherein chronic leukemia progresses slowly over time.

Browse through 29 Market Tables and 22 Figures spread through 110 Pages and in-depth TOC on “Global Leukemia Therapeutics Market by Type & Size- Forecast to 2016 – 2022”.

Request Free Sample copy of Leukemia Therapeutics Market Report @

Global Leukemia Therapeutics market is primarily driven by growing incidences of target disease across the globe. Other major driving factors are the development of novel agents and combination therapy with lesser side effects and better survival. However, the high price of combination therapies and clinical trials coupled with possible adverse events or side effects are the major restraints that may limit the growth of the market. Nonetheless increasing focus on personalized medicine coupled with a huge investment in anti-leukemia therapeutics research across the globe are likely to disclose the new avenues for Leukemia Therapeutics market in the near future.

Based on the type, leukemia therapeutics market has been segmented into acute leukemia, chronic leukemia, and others. Acute leukemia segment is subdivided into acute lymphatic leukemia and acute myeloid leukemia whereas chronic leukemia is sub-segmented as chronic lymphatic leukemia and chronic myeloid leukemia. The market is segmented into chemotherapy, biological therapy, radiation therapy, targeted therapy and other based on therapy.

Browse the full "Leukemia Therapeutics Market by Type (Acute, Chronic and other), Therapy (Chemotherapy, Biological Therapy, Radiation Therapy, Targeted Therapy and Others) and Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022 " report at

North America represents developed regional markets for leukemia therapeutics and is expected to see the rapid growth in the years to come. The U.S. is by far the leading leukemia therapeutics market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the high prevalence of leukemia coupled with well-developed healthcare infrastructure and an increase in research and development of leukemia therapeutics. Moreover, the disposable income and reimbursement of life-threatening diseases are very high in this region which promotes the growth of leukemia therapeutics market. 

Europe was the second largest regional market and is expected to show significant growth in the years to come. This growth is mainly due to increase in a number of patients diagnosed with leukemia and entry of novel therapies in the market.

Inquire more about this report @

Asia-Pacific is expected to witness slow growth in the near future. This low growth is mainly attributed to the lower incidence rate of leukemia in the Asian population. Thus Asia Pacific will be slow-growing markets in leukemia therapeutics market.

In Middle East & Africa; African region is projected to register moderate growth rate due to the high cost of leukemia therapies. Latin America is another important regional market and is expected to experience moderate growth over the forecast period. Thus, all the aforementioned parameters are expected to propel the market growth in this region.

Request customized copy of report @

Some of the key players in leukemia therapeutics market include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc., Genzyme Corporation,  AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others.

Purchase a direct copy of report with TOC @ 

This report segments the global leukemia therapeutics market as follows:

Global Leukemia Therapeutics Market: Type Segment Analysis

  • Chronic leukemia
  • Chronic lymphatic leukemia
  • Chronic myeloid leukemia
  • Acute leukemia
  • Acute lymphatic leukemia
  • Acute myeloid leukemia
  • Others

Global Leukemia Therapeutics Market: Therapy Segment Analysis

  • Chemotherapy
  • Biological Therapy
  • Radiation therapy
  • Targeted therapy
  • Other

Global Leukemia Therapeutics Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Report:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn:

Follow Us Twitter:

Contact Us:

Joel John

4283, Express Lane, Suite 634-143,
Sarasota, Florida 34249, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651